Scholars Central

Short communicationPublished 22 Jul 2016

Combining EGF receptor inhibitors with chemotherapy or chemoradiotherapy in patients with non-small-cell lung cancer

Authors: Bruno R Bastos, Rogerio C Lilenbaum

Clinical Practice

Volume 8 · Issue 1 · Pages 9

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The use of EGF receptor inhibitors has recently been incorporated into the armamentarium of agents available to treat patients with non-small-cell lung cancer. Their use in combination with chemotherapy and radiotherapy has been investigated in Phase II and III trials. The use of EGF receptor tyrosine kinase inhibitors in combination with chemotherapy has been somewhat disappointing, whereas the use of anti- EGF receptor monoclonal cetuximab in combination with chemotherapy has provided mixed results. The use of cetuximab in combination with chemotherapy and radiotherapy in patients with locally advanced disease has generated encouraging results in Phase II trials, and Phase III trials are currently ongoing. The identification of molecular biomarkers to predict benefit is a work in progress.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Practice.

All its articles

Article · 28 Mar 2025

Using

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Practice
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Bruno R Bastos”
  • BylineArticles whose byline prints “Rogerio C Lilenbaum”